Role of evidence from observational studies in the process of health care decision making

Similar documents
GLOSSARY OF GENERAL TERMS

What is indirect comparison?

DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2

RARE-Bestpractices Conference

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Critical Appraisal Series

A Systematic Review of the Efficacy and Clinical Effectiveness of Group Analysis and Analytic/Dynamic Group Psychotherapy

The Royal College of Pathologists Journal article evaluation questions

GATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms

1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010)

Appraising the Literature Overview of Study Designs

Washington, DC, November 9, 2009 Institute of Medicine

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

4/10/2018. Choosing a study design to answer a specific research question. Importance of study design. Types of study design. Types of study design

Are the likely benefits worth the potential harms and costs? From McMaster EBCP Workshop/Duke University Medical Center

User s guide to the checklist of items assessing the quality of randomized controlled trials of nonpharmacological treatment

Copyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD

Overview of Study Designs in Clinical Research

British Geriatrics Society

On population diversity in clinical trials A few remarks. Prof. Olaf M. Dekkers Dept clinical epidemiology & internal medicine LUMC

Clinical problems and choice of study designs

From single studies to an EBM based assessment some central issues

EVIDENCE AND RECOMMENDATION GRADING IN GUIDELINES. A short history. Cluzeau Senior Advisor NICE International. G-I-N, Lisbon 2 November 2009

Meta-analyses: analyses:

In keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:

Evidence Based Practice

CRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern

BACKGROUND AND SCIENTIFIC RATIONALE. Protocol Code: ISRCTN V 1.0 date 30 Jan 2012

Results. NeuRA Hypnosis June 2016

Evidence-based medicine and guidelines: development and implementation into practice

Outline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:

Randomized Controlled Trial

Mapping the Informed Health Choices (IHC) Key Concepts (KC) to core concepts for the main steps of Evidence-Based Health Care (EBHC).

National Audit of Dementia

The comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.

How to design Homeopathy clinical randomised trials that

Clinical Epidemiology for the uninitiated

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

RATING OF A RESEARCH PAPER. By: Neti Juniarti, S.Kp., M.Kes., MNurs

Systematic reviews: From evidence to recommendation. Marcel Dijkers, PhD, FACRM Icahn School of Medicine at Mount Sinai

Evidence- and Value-based Solutions for Health Care Clinical Improvement Consults, Content Development, Training & Seminars, Tools

GATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)

Embedding pragmatic trials within databases of electronic health records / disease registries Tjeerd van Staa

Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial Pinnock H, McKenzie L, Price D, Sheikh A

Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study

Introduction to systematic reviews/metaanalysis

Systematic Reviews. Simon Gates 8 March 2007

Technology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264

CHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S

Introduzione al metodo GRADE

An introduction to Quality by Design. Dr Martin Landray University of Oxford

Problem solving therapy

Garbage in - garbage out? Impact of poor reporting on the development of systematic reviews

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Controlled Trials. Spyros Kitsiou, PhD

Determinants of quality: Factors that lower or increase the quality of evidence

Cochrane Pregnancy and Childbirth Group Methodological Guidelines

Checklist for appraisal of study relevance (child sex offenses)

Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions

Surveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.

Systematic Reviews and Meta- Analysis in Kidney Transplantation

Clinical research in AKI Timing of initiation of dialysis in AKI

Improving reporting for observational studies: STROBE statement

Professional organisation statement template

Trial Designs. Professor Peter Cameron

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

Workshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.

Treatment changes in cancer clinical trials: design and analysis

Gastrointestinal haemorrhage

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Contents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7

Statistical Analysis Plans

Evidence-based Laboratory Medicine. Prof AE Zemlin Chemical Pathology Tygerberg Hospital

Avoiding common errors in research reporting:

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493

Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487

Can Audit and Feedback Reduce Antibiotic Prescribing in Dentistry?

CONSORT 2010 checklist of information to include when reporting a randomised trial*

ARCHE Risk of Bias (ROB) Guidelines

Analytic Study Design

Why is ILCOR moving to GRADE?

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Ruxolitinib for the treatment of myelofibrosis

Technology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta459

Making pragmatic trials work

Cluster Randomised Trials: Sources of Bias. Ada Keding Professor David Torgerson

Concentration and choice in the provision of hospital services: summary report NHS Centre for Reviews and Dissemination

Objectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions

The role of Randomized Controlled Trials

MEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany

SYSTEMATIC REVIEW: AN APPROACH FOR TRANSPARENT RESEARCH SYNTHESIS

PROSPERO International prospective register of systematic reviews

Smoke and mirrors: where is the K for KT? Jeremy Grimshaw MD, PhD

The Burden of Medical Error The Case for Clinical Decision Support

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

Similar mortality rates in hip fracture patients over the past 31 years

Department of OUTCOMES RESEARCH

Commissioning Brief - Background Information. Exercise training for people with pulmonary hypertension

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

Transcription:

Role of evidence from observational studies in the process of health care decision making Jan van der Meulen Health Services Research Unit London School of Hygiene and Tropical Medicine Clinical Effectiveness Unit Royal College of Surgeons of England

Clinical Effectiveness Unit The Royal College of Surgeons of England Core activity: Assessing the quality of surgical care in the UK Also: Carrying out research on clinical and cost effectiveness Developing clinical practice guidelines Assessing the quality of care: basic questions no benchmark benchmark available processes what are we doing? are we doing what we should be doing? determinants outcomes what is the outcome of what we are doing? are we doing it well?

Role of evidence from observational studies to compare health care interventions Randomisation may be: Unnecessary Dramatic effect -> confounding irrelevant Inappropriate Rare outcomes, outcomes far in the future Impact of random allocation on effectiveness Impossible Lack willingness to participate (clinicians and patients) Ethical or political objections Contamination Scale Inadequate Clinicians not representative, patients atypical Efficacy rather than effectiveness N Black, BMJ 1996;312:1215 Sources of bias in studies comparing health care interventions Selection for inclusion Treatment allocation -> confounding by indication Co-intervention Loss to follow-up Assessment of outcomes

Remedies against bias Selection for inclusion Treatment allocation Co-intervention Loss to follow-up Assessment of outcome RCT Explicit in- and exclusion criteria Randomisation Blinding Completeness of follow-up Blinded outcome assessment Non-randomised study Explicit in- and exclusion criteria Case-mix adjustment Measurement of interventions Completeness of follow-up Blinded outcome assessment RCT and non-randomised studies of arthroplasty versus internal fixation for fractured neck of femur 14 randomised studies (n=3108) and 13 non-randomised studies (n=1901) Mortality Revision RR for arthroplasty RCT 1.04 0.24 Nonrandomised 1.44 0.38 Authors are unable to identify reasons for these differences * M Bhandari et al, Arch Orthop Trauma Surg 2004;124:10

Review of empirical comparisons of randomised and non-randomised studies Reviews were included if They compared quantitative results between RCTs and nonrandomised studies of the same technique They had accumulated results from several of these comparisons across healthcare interventions Eight reviews were found with considerable overlap 7 medical interventions and 1 psychological intervention J Deeks et al, Health Technol Assess 2003:7(27) Review of empirical comparisons of randomised and non-randomised studies cont d Conflicting results: 5 studies concluded that there were differences between randomised and non-randomised studies, but without a consistent pattern indicating systematic bias 1 study (oldest 1982) found overestimation of effect with nonrandomised studies 2 studies concluded that results of randomised and nonrandomised studies were remarkably similar Other results: 1 study concluded that results of RCTs were more consistent and 1 study that they were less consistent 2 studies agreed that case-mix adjustment did not reduce differences between randomised and non-randomised findings

Review of empirical comparisons of randomised and non-randomised studies cont d Critical evaluation of reviews Publication bias of primary study and of the reviews Differences between RCTs and non-randomised studies in participants, interventions and outcomes study methodology Large variation in criteria for what is different or similar Conclusions Results of RCT and non-randomised studies sometimes, but not always, differ Similarities and differences might be explicable by other confounding factors (e.g. era, populations, dosage, length of follow-up) -> comparison unfair due to meta-confounding Observational data to enhance results of RCTs PROWESS trial: Recombinant human activated protein C versus placebo for severe sepsis on intensive care Trial was stopped after interim analysis showed reduced 28-day mortality with agent (24.7% versus 30.8%) Are these results generalisable to intensive care practice in UK (or Germany?) A Padkin et al, BMJ 2001;323:923

Observational data to enhance results of RCTs Cont d UK audit of patient outcome on intensive care to assess: Generalisability of PROWESS results to UK practice 28% of all intensive care admissions met definition for severe sepsis used in PROWESS trail Hospital mortality in UK is 44.7% compared to 30.8% at 28 days in PROWESS Financial implications of recommending use of agent About 10,000 patients eligible for drug each year -> potential costs 30m - 50 Effectiveness of agent after introduction in UK practice May include patients not eligible for PROWESS trial Case-mix adjustment important! Observational data to enhance results of RCTs Before RCT Identify uncertainty and generate hypotheses Estimate the parameters for sample size calculations After RCT Evaluate outcome over longer period, in wider context and in different populations Study link between efficacy and effectiveness Explore impact on clinical practice / health service Examine uptake of new treatment

Observational data to support individualised decision making Not every patient is the same RCTs do not give the answer for individual patients Clinical profile of patients important Implications for clinical research Trial design: anticipate individual risk management / subgroup analysis Observational studies for prognostic information Decision analysis to combine data from RCTs and studies on prognosis. European Carotid Surgery Trial PM Rothwell, Lancet 1999;353:2105

Individualised decision making for carotid endarterectomy Decision for individual patients depends on balance between risk of stroke and death resulting from surgery extra risk of ipsilateral stroke without surgery Crucial question: can we differentiate patients in terms of stroke risk? surgical risk?

Most important question of evidence-based medicine: whom to treat with what RCT evidence from selected and homogenous groups Observational data on prognosis Individualised decision making incorporating patients preferences and circumstances

Summary Role for observational studies in absence of RCTs to evaluate interventions Differences between results of non-randomised studies and RCTs can not be predicted Observational data can enhance results from RCTs Observational data needed for individualised decision making